CA2966359A1 - Apilimod for use in the treatment of renal cancer - Google Patents

Apilimod for use in the treatment of renal cancer Download PDF

Info

Publication number
CA2966359A1
CA2966359A1 CA2966359A CA2966359A CA2966359A1 CA 2966359 A1 CA2966359 A1 CA 2966359A1 CA 2966359 A CA2966359 A CA 2966359A CA 2966359 A CA2966359 A CA 2966359A CA 2966359 A1 CA2966359 A1 CA 2966359A1
Authority
CA
Canada
Prior art keywords
apilimod
composition
cancer
therapeutic agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2966359A
Other languages
English (en)
French (fr)
Inventor
Neil BEEHARRY
Sophia GAYLE
Sean LANDRETTE
Paul Beckett
Chris Conrad
Tian Xu
Jonathan M. Rothberg
Henri Lichenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OrphAI Therapeutics Inc
Original Assignee
LAM Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAM Therapeutics Inc filed Critical LAM Therapeutics Inc
Publication of CA2966359A1 publication Critical patent/CA2966359A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2966359A 2014-11-07 2015-11-06 Apilimod for use in the treatment of renal cancer Abandoned CA2966359A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
US62/077,127 2014-11-07
PCT/US2015/059512 WO2016073877A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of renal cancer

Publications (1)

Publication Number Publication Date
CA2966359A1 true CA2966359A1 (en) 2016-05-12

Family

ID=54548302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2966359A Abandoned CA2966359A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of renal cancer

Country Status (16)

Country Link
US (3) US10206910B2 (enExample)
EP (2) EP3215158B1 (enExample)
JP (1) JP6705828B2 (enExample)
KR (1) KR20170098812A (enExample)
CN (1) CN107249638B (enExample)
AU (1) AU2015342869A1 (enExample)
BR (1) BR112017008799A2 (enExample)
CA (1) CA2966359A1 (enExample)
ES (1) ES2741399T3 (enExample)
HU (1) HUE044557T2 (enExample)
IL (1) IL251905B (enExample)
MX (1) MX377593B (enExample)
PL (1) PL3215158T3 (enExample)
PT (1) PT3215158T (enExample)
RU (1) RU2727802C2 (enExample)
WO (1) WO2016073877A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659716B (zh) 2014-01-24 2021-03-12 人工智能治疗公司 阿吡莫德组合物及其使用方法
ES2734081T3 (es) * 2014-11-07 2019-12-04 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de melanoma
ES2741399T3 (es) 2014-11-07 2020-02-10 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de cáncer renal
RU2018130070A (ru) * 2016-01-21 2020-02-21 Лэм Терапьютикс, Инк. Биомаркеры для лечения рака при помощи апилимода
CA3034453A1 (en) * 2016-08-25 2018-03-01 AI Therapeutics, Inc. Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling
JP7199349B2 (ja) * 2016-10-12 2023-01-05 エイアイ・セラピューティクス・インコーポレーテッド アピリモド組成物およびそれをアルツハイマー病の処置に使用するための方法
US11066410B2 (en) 2017-03-24 2021-07-20 3100 Central Expressway Llc Fused triazolo-pyrimidine compounds having useful pharmaceutical application
JP7517988B2 (ja) 2018-01-26 2024-07-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ｖｅｇｆ剤を使用した血管新生障害の治療のための方法および組成物
BR112020016256A2 (pt) * 2018-02-21 2020-12-15 AI Therapeutics, Inc. Terapia de combinação com apilimod e agentes gluta-matérgicos
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
CN114306370A (zh) * 2021-12-31 2022-04-12 北京悦康科创医药科技股份有限公司 反义寡核苷酸在制备治疗肾癌药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DK1921169T3 (da) 1993-11-12 2012-06-04 Phri Properties Inc Hybridiseringssonder til nukleinsyredetektion, universelle stamceller, fremgangsmåder og kits
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
NZ584288A (en) 2004-02-06 2011-10-28 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
CA2563895C (en) 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
WO2006029385A2 (en) 2004-09-08 2006-03-16 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
TW200720256A (en) 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
EP2385053B1 (en) 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
TW200738725A (en) 2006-01-25 2007-10-16 Osi Pharm Inc Unsaturated mTOR inhibitors
AU2007272950B2 (en) 2006-07-12 2012-11-01 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
EP2118087B1 (en) 2007-02-06 2012-03-28 Novartis AG Pi 3-kinase inhibitors and methods of their use
RU2438664C2 (ru) 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5258331B2 (ja) 2008-03-03 2013-08-07 ロート製薬株式会社 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
TR201800962T4 (en) 2010-03-08 2018-03-21 Sloan Kettering Inst Cancer Res CDC7 KINAZI INHIBITORS AND THEIR USAGE
WO2011122620A1 (ja) * 2010-03-29 2011-10-06 味の素株式会社 フェニルアラニン誘導体を含有する医薬製剤
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
US8709419B2 (en) * 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
CA2817931C (en) 2010-11-19 2017-10-31 Ecole Polytechnique Federale De Lausanne (Epfl) 2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102418979B1 (ko) 2012-05-15 2022-07-11 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
HK1214128A1 (zh) 2012-10-05 2016-07-22 Bluelink Pharmaceuticals, Inc. 癌症的治療
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
CN106659716B (zh) 2014-01-24 2021-03-12 人工智能治疗公司 阿吡莫德组合物及其使用方法
ES2741399T3 (es) 2014-11-07 2020-02-10 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de cáncer renal
ES2734081T3 (es) 2014-11-07 2019-12-04 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de melanoma
KR101761573B1 (ko) 2014-12-29 2017-07-26 주식회사 인트론바이오테크놀로지 신규한 장출혈성 대장균 박테리오파지 Ｅｓｃ-ＣＨＰ-1 및 이의 장출혈성 대장균 증식 억제 용도
HK1245158A1 (zh) 2015-02-03 2018-08-24 AI Therapeutics, Inc. 阿吡莫德组合物及其使用方法
WO2016160102A1 (en) 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
US12030896B2 (en) 2018-07-05 2024-07-09 Mayo Foundation For Medical Education And Research PIKfyve inhibitors
US20210077500A1 (en) 2019-09-12 2021-03-18 Al Therapeutics, Inc. Pikfyve inhibitors for cancer therapy

Also Published As

Publication number Publication date
IL251905A0 (en) 2017-06-29
US20190201385A1 (en) 2019-07-04
CN107249638A (zh) 2017-10-13
EP3215158B1 (en) 2019-05-08
JP2017535601A (ja) 2017-11-30
KR20170098812A (ko) 2017-08-30
EP3581184B1 (en) 2021-02-24
US11166944B2 (en) 2021-11-09
ES2741399T3 (es) 2020-02-10
EP3215158A1 (en) 2017-09-13
PT3215158T (pt) 2019-08-23
US20170333408A1 (en) 2017-11-23
RU2727802C2 (ru) 2020-07-24
JP6705828B2 (ja) 2020-06-03
HUE044557T2 (hu) 2019-11-28
AU2015342869A1 (en) 2017-06-15
RU2017119065A3 (enExample) 2019-06-05
US20200297706A1 (en) 2020-09-24
CN107249638B (zh) 2021-05-14
MX377593B (es) 2025-03-10
WO2016073877A1 (en) 2016-05-12
RU2017119065A (ru) 2018-12-07
PL3215158T3 (pl) 2019-11-29
IL251905B (en) 2021-03-25
MX2017006015A (es) 2017-11-17
EP3581184A1 (en) 2019-12-18
US10206910B2 (en) 2019-02-19
BR112017008799A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
US11166944B2 (en) Apilimod compositions and methods for using same in the treatment of renal cancer
US11266654B2 (en) Apilimod compositions and methods for using same
US20180078561A1 (en) Active metabolites of apilimod and uses thereof
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
HK40018267B (en) Apilimod for use in the treatment of renal cancer
HK40018267A (en) Apilimod for use in the treatment of renal cancer
HK1242205A1 (en) Apilimod for use in the treatment of renal cancer
HK1242205B (en) Apilimod for use in the treatment of renal cancer
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma
NZ722491B2 (en) Apilimod compositions and methods for using same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201016

EEER Examination request

Effective date: 20201016

FZDE Discontinued

Effective date: 20230510